If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 ...

A clinical trial funded by the National Institute of Health (NIH) revealed there is no significant difference in the effectiveness of furosemide and torsemide, two heart failure drugs, when it comes ...

A Prescription Drug User Fee Act target date of March 6, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...